{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:31:21Z","timestamp":1789061481049,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82360367"],"award-info":[{"award-number":["82360367"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04330-4","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:12:33Z","timestamp":1779117153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A MOF-in-MOF nanoplatform for photothermal\/chemodynamic therapy that enhances antitumor immunity through targeted suppression of the COX-2\/PGE2 axis"],"prefix":"10.1186","volume":"24","author":[{"given":"Yiling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aojie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"4330_CR1","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1016\/j.apsb.2023.05.018","volume":"13","author":"Q Liu","year":"2023","unstructured":"Liu Q, Zou J, Chen Z, He W, Wu W. Current research trends of nanomedicines. Acta Pharm Sin B. 2023;13:4391\u2013416.","journal-title":"Acta Pharm Sin B"},{"key":"4330_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.apsb.2024.12.007","volume":"15","author":"Y Liu","year":"2025","unstructured":"Liu Y, Zhang Y, Li H, Hu TY. Recent advances in the bench-to-bedside translation of cancer nanomedicines. Acta Pharm Sin B. 2025;15:97\u2013122.","journal-title":"Acta Pharm Sin B"},{"key":"4330_CR3","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1039\/C9BM01992H","volume":"8","author":"RH Jin","year":"2020","unstructured":"Jin RH, Xie JR, Yang XS, Tian Y, Yuan PY, Bai YK, Liu SY, Cai BL, Chen X. A tumor-targeted nanoplatform with stimuli-responsive cascaded activities for multiple model tumor therapy. Biomater Sci. 2020;8:1865\u201374.","journal-title":"Biomater Sci"},{"key":"4330_CR4","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41563-020-0755-z","volume":"19","author":"B Ouyang","year":"2020","unstructured":"Ouyang B, Poon W, Zhang Y-N, Lin ZP, Kingston BR, Tavares AJ, Zhang Y, Chen J, Valic MS, Syed AM, et al. The dose threshold for nanoparticle tumour delivery. Nat Mater. 2020;19:1362\u201371.","journal-title":"Nat Mater"},{"key":"4330_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","volume":"240","author":"Y-N Zhang","year":"2016","unstructured":"Zhang Y-N, Poon W, Tavares AJ, McGilvray ID, Chan WCW. Nanoparticle\u2013liver interactions: cellular uptake and hepatobiliary elimination. J Controlled Release. 2016;240:332\u201348.","journal-title":"J Controlled Release"},{"key":"4330_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fimmu.2020.00218","volume":"11","author":"CI Colino","year":"2020","unstructured":"Colino CI, Lanao JM, Gutierrez-Millan C. Targeting of Hepatic Macrophages by Therapeutic Nanoparticles. Front Immunol. 2020;11:218.","journal-title":"Front Immunol"},{"key":"4330_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s11671-024-04118-1","volume":"19","author":"U Havelikar","year":"2024","unstructured":"Havelikar U, Ghorpade KB, Kumar A, Patel A, Singh M, Banjare N, Gupta PN. Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines. Discover Nano. 2024;19:165.","journal-title":"Discover Nano"},{"key":"4330_CR8","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.2147\/IJN.S132780","volume":"12","author":"S Shen","year":"2017","unstructured":"Shen S, Wu Y, Liu Y, Wu D. High drug-loading nanomedicines: progress, current status, and prospects. Int J Nanomed. 2017;12:4085\u2013109.","journal-title":"Int J Nanomed"},{"key":"4330_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jconrel.2020.10.014","volume":"329","author":"S Karaosmanoglu","year":"2021","unstructured":"Karaosmanoglu S, Zhou M, Shi B, Zhang X, Williams GR, Chen X. Carrier-free nanodrugs for safe and effective cancer treatment. J Control Release. 2021;329:805\u201332.","journal-title":"J Control Release"},{"key":"4330_CR10","doi-asserted-by":"publisher","first-page":"102102","DOI":"10.1016\/j.apmt.2024.102102","volume":"37","author":"RH Jin","year":"2024","unstructured":"Jin RH, Li JL, Huang BY, Lu JY, Huang J, Wu LJ, Mo XF, Li Y, Su B, Ouyang A, et al. Amelioration of osteoarthritis through salicylic acid nano-formulated self-therapeutic prodrug for the prolonged launch of salicylic acid to damaged cartilage. Appl Mater Today. 2024;37:102102.","journal-title":"Appl Mater Today"},{"key":"4330_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1186\/s12951-025-03765-5","volume":"23","author":"Z Wang","year":"2025","unstructured":"Wang Z, Su B, Ouyang A, Liang Z, Yuan P, Qin X, Li Y, Huang X, Fan L, Guo H, Jin R. Reengineering glycyrrhetinic acid into a therapeutic oligomer for targeted tumor therapy with cardioprotection. J Nanobiotechnol. 2025;23:715.","journal-title":"J Nanobiotechnol"},{"key":"4330_CR12","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1136\/gut.35.9.1282","volume":"35","author":"SP Travis","year":"1994","unstructured":"Travis SP, Tysk C, de Silva HJ, Sandberg-Gertz\u00e9n H, Jewell DP, J\u00e4rnerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut. 1994;35:1282\u20136.","journal-title":"Gut"},{"key":"4330_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41563-019-0503-4","volume":"18","author":"Y Yuan","year":"2019","unstructured":"Yuan Y, Zhang J, Qi X, Li S, Liu G, Siddhanta S, Barman I, Song X, McMahon MT, Bulte JWM. Furin-mediated intracellular self-assembly of olsalazine nanoparticles for enhanced magnetic resonance imaging and tumour therapy. Nat Mater. 2019;18:1376\u201383.","journal-title":"Nat Mater"},{"key":"4330_CR14","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1002\/anie.202014839","volume":"60","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Raj P, Zhang J, Siddhanta S, Barman I, Bulte JWM. Furin-Mediated Self-Assembly of Olsalazine Nanoparticles for Targeted Raman Imaging of Tumors. Angew Chem. 2021;60:3923\u20137.","journal-title":"Angew Chem"},{"key":"4330_CR15","doi-asserted-by":"publisher","first-page":"129521","DOI":"10.1016\/j.seppur.2024.129521","volume":"355","author":"J Lu","year":"2025","unstructured":"Lu J, Ouyang A, Wang Z, Li Y, Qin X, Su B, Huang X, Li K, Luo J, Xu G, et al. Enhancing bimetallic redox cycling by Olsalazine-based MOF to achieve efficient removal of ofloxacin. Sep Purif Technol. 2025;355:129521.","journal-title":"Sep Purif Technol"},{"key":"4330_CR16","doi-asserted-by":"publisher","first-page":"138849","DOI":"10.1016\/j.jcis.2025.138849","volume":"702","author":"J Lu","year":"2026","unstructured":"Lu J, Li Y, Qin X, Wang Z, Ouyang A, Su B, Guo H, Yang X, Shen Z, Li J, et al. A clinically inspired olsalazine-based metal-organic framework enables a universal nanodrugs platform for diverse disease. J Colloid Interface Sci. 2026;702:138849.","journal-title":"J Colloid Interface Sci"},{"key":"4330_CR17","doi-asserted-by":"publisher","first-page":"1065438","DOI":"10.3389\/fphar.2022.1065438","volume":"13","author":"M Li","year":"2022","unstructured":"Li M, Zhang W, Xu X, Liu G, Dong M, Sun K, Zhang P. Nanosystems for chemodynamic based combination therapy: Strategies and recent advances. Front Pharmacol. 2022;13:1065438.","journal-title":"Front Pharmacol"},{"key":"4330_CR18","doi-asserted-by":"publisher","first-page":"eadq3870","DOI":"10.1126\/sciadv.adq3870","volume":"11","author":"H Zhang","year":"2025","unstructured":"Zhang H, Lv J, Wu H, He Y, Li M, Wu C, Lv D, Liu Y, Yang H. Endogenous\/exogenous dual-responsive nanozyme for photothermally enhanced ferroptosis-immune reciprocal synergistic tumor therapy. Sci Adv. 2025;11:eadq3870.","journal-title":"Sci Adv"},{"key":"4330_CR19","doi-asserted-by":"publisher","first-page":"101542","DOI":"10.1016\/j.mtbio.2025.101542","volume":"31","author":"B Zheng","year":"2025","unstructured":"Zheng B, Wang H, Zhai S, Li J, Lu K. Mitochondria-targeted photothermal-chemodynamic therapy enhances checkpoint blockade immunotherapy on colon cancer. Mater Today Bio. 2025;31:101542.","journal-title":"Mater Today Bio"},{"key":"4330_CR20","doi-asserted-by":"publisher","first-page":"102749","DOI":"10.1016\/j.mtbio.2025.102749","volume":"36","author":"A Ouyang","year":"2026","unstructured":"Ouyang A, Qin X, Su B, Mo S, Jiang J, Wang Z, Li Y, Lu J, Lin Y, Wang J, et al. Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling. Mater Today Bio. 2026;36:102749.","journal-title":"Mater Today Bio"},{"key":"4330_CR21","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.engmed.2025.100103","volume":"2","author":"F Jiang","year":"2025","unstructured":"Jiang F, Qin Y, Sun X, Gao L, Feng Z, Li F, Lai Z, Liang X. Immunogenic nano-phthalocyanine enables oxygen-economic photodynamic therapy for hepatocellular carcinoma. EngMedicine. 2025;2:100103.","journal-title":"EngMedicine"},{"key":"4330_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400367","author":"JM Lai","year":"2024","unstructured":"Lai JM, Chen PL, Shi QY, Xie YQ, Jiaerheng G, Liu LH. A self\u2010delivery nanodrug simultaneously inhibits COX\u20102\/PGE2 mediated inflammation and downregulates PD\u2010L1 to boost photoimmunotherapy. Adv Healthc Mater. 2024. https:\/\/doi.org\/10.1002\/adhm.202400367.","journal-title":"Adv Healthc Mater"},{"key":"4330_CR23","doi-asserted-by":"publisher","first-page":"122695","DOI":"10.1016\/j.biomaterials.2024.122695","volume":"311","author":"P Zhang","year":"2024","unstructured":"Zhang P, Zhong D, Yu Y, Wang L, Li Y, Liang Y, Shi Y, Duan M, Li B, Niu H. Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy. Biomaterials. 2024;311:122695.","journal-title":"Biomaterials"},{"key":"4330_CR24","doi-asserted-by":"publisher","first-page":"100883","DOI":"10.1016\/j.apmt.2020.100883","volume":"21","author":"RH Jin","year":"2020","unstructured":"Jin RH, Wang Q, Dou G, Bai YK, Liu SY, Cai BL, Chen X. Stimuli responsive nanoplatform with mitochondria-specific multiple model therapeutics for effective tumor treatment. Appl Mater Today. 2020;21:100883.","journal-title":"Appl Mater Today"},{"key":"4330_CR25","first-page":"1","volume-title":"Biomed. Appl. Funct. Nanomater.","author":"A Sosnik","year":"2018","unstructured":"Sosnik A. Chap. 1 - From the \u201cMagic Bullet\u201d to Advanced Nanomaterials for Active Targeting in Diagnostics and Therapeutics. In: Biomed. Appl. Funct. Nanomater. 2018. p. 1\u201332."},{"key":"4330_CR26","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1039\/D4CS01061B","volume":"54","author":"F Afshariazar","year":"2025","unstructured":"Afshariazar F, Morsali A. Mixed-valence metal\u2013organic frameworks: concepts, opportunities, and prospects. Chem Soc Rev. 2025;54:1318\u201383.","journal-title":"Chem Soc Rev"},{"key":"4330_CR27","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1021\/acsmaterialslett.3c00322","volume":"5","author":"K Sun","year":"2023","unstructured":"Sun K, Yu J, Hu J, Xu Q, Liu M, Cai Z, et al. Pemetrexed\u2013poly(salicylic acid) assemblies reshape immunosuppressive tumor microenvironment for enhanced chemo-immunotherapy. ACS Mater Lett. 2023;5:1581\u201392.","journal-title":"ACS Mater Lett"},{"key":"4330_CR28","doi-asserted-by":"publisher","first-page":"2006004","DOI":"10.1002\/smll.202006004","volume":"17","author":"X Dai","year":"2021","unstructured":"Dai X, Zhao X, Liu Y, Chen B, Ding X, Zhao N, Xu F-J. Controlled Synthesis and Surface Engineering of Janus Chitosan-Gold Nanoparticles for Photoacoustic Imaging-Guided Synergistic Gene\/Photothermal Therapy. Small. 2021;17:2006004.","journal-title":"Small"},{"key":"4330_CR29","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1021\/nn506687t","volume":"9","author":"S Wang","year":"2015","unstructured":"Wang S, Riedinger A, Li H, Fu C, Liu H, Li L, Liu T, Tan L, Barthel MJ, Pugliese G, et al. Plasmonic Copper Sulfide Nanocrystals Exhibiting Near-Infrared Photothermal and Photodynamic Therapeutic Effects. ACS Nano. 2015;9:1788\u2013800.","journal-title":"ACS Nano"},{"key":"4330_CR30","doi-asserted-by":"publisher","first-page":"2205414","DOI":"10.1002\/smll.202205414","volume":"19","author":"X Chu","year":"2023","unstructured":"Chu X, Zhang L, Li Y, He Y, Zhang Y, Du C. NIR Responsive Doxorubicin-Loaded Hollow Copper Ferrite @ Polydopamine for Synergistic Chemodynamic\/Photothermal\/Chemo-Therapy. Small. 2023;19:2205414.","journal-title":"Small"},{"key":"4330_CR31","doi-asserted-by":"publisher","first-page":"1801961","DOI":"10.1002\/adfm.201801961","volume":"28","author":"R Jin","year":"2018","unstructured":"Jin R, Liu Z, Bai Y, Zhou Y, Gooding JJ, Chen X. Core\u2013satellite mesoporous silica\u2013gold nanotheranostics for biological stimuli triggered multimodal cancer therapy. Adv Funct Mater. 2018;28:1801961.","journal-title":"Adv Funct Mater"},{"key":"4330_CR32","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1016\/j.cclet.2021.03.084","volume":"32","author":"RH Jin","year":"2021","unstructured":"Jin RH, Liu ZN, Liu T, Yuan PY, Bai YK, Chen X. Redox-responsive micelles integrating catalytic nanomedicine and selective chemotherapy for effective tumor treatment. Chin Chem Lett. 2021;32:3076\u201382.","journal-title":"Chin Chem Lett"},{"key":"4330_CR33","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ijbiomac.2022.03.139","volume":"207","author":"Q Liu","year":"2022","unstructured":"Liu Q, Ding X, Xu X, Lai H, Zeng Z, Shan T, Zhang T, Chen M, Huang Y, Huang Z, et al. Tumor-targeted hyaluronic acid-based oxidative stress nanoamplifier with ROS generation and GSH depletion for antitumor therapy. Int J Biol Macromol. 2022;207:771\u201383.","journal-title":"Int J Biol Macromol"},{"key":"4330_CR34","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022;12:2115\u201332.","journal-title":"Theranostics"},{"key":"4330_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41419-024-06939-5","volume":"15","author":"X An","year":"2024","unstructured":"An X, Yu W, Liu J, Tang D, Yang L, Chen X. Oxidative cell death in cancer: mechanisms and therapeutic opportunities. Cell Death Dis. 2024;15:556.","journal-title":"Cell Death Dis"},{"key":"4330_CR36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11:1013.","journal-title":"Cell Death Dis"},{"key":"4330_CR37","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/s41565-025-01922-3","volume":"20","author":"Y Wu","year":"2025","unstructured":"Wu Y, Chen W, Deng J, Cao X, Yang Z, Chen J, Tan Q, Zhou E, Li M, Liu J, et al. Tumour-derived microparticles obtained through microwave irradiation induce immunogenic cell death in lung adenocarcinoma. Nat Nanotechnol. 2025;20:1119\u201330.","journal-title":"Nat Nanotechnol"},{"key":"4330_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23:445\u201360.","journal-title":"Nat Rev Drug Discov"},{"key":"4330_CR39","doi-asserted-by":"publisher","first-page":"2410214","DOI":"10.1002\/smll.202410214","volume":"21","author":"X Feng","year":"2025","unstructured":"Feng X, Zhang Y, Lin W, Li J, Wu F, Lu Q, Song H, Zhang H, Lan F, Lu J. A Self-Amplifying Photodynamic Biomedicine for Cascade Immune Activation Against Triple-Negative Breast Cancer. Small. 2025;21:2410214.","journal-title":"Small"},{"key":"4330_CR40","doi-asserted-by":"publisher","first-page":"101266","DOI":"10.1016\/j.nantod.2021.101266","volume":"40","author":"Y Wang","year":"2021","unstructured":"Wang Y, Xu C, Meng M, Lin L, Hu Y, Hao K, Sheng S, Zhang S, Wu J, Liu F, et al. Precise regulation of inflammation and immunosuppressive microenvironment for amplified photothermal\/immunotherapy against tumour recurrence and metastasis. Nano Today. 2021;40:101266.","journal-title":"Nano Today"},{"key":"4330_CR41","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1158\/2159-8290.CD-20-1815","volume":"11","author":"VS Pelly","year":"2021","unstructured":"Pelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, Blanco-Gomez A, Banyard A, Bromley CP, Flanagan E, et al. Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy. Cancer Discov. 2021;11:2602\u201319.","journal-title":"Cancer Discov"},{"key":"4330_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","volume":"15","author":"B Liu","year":"2015","unstructured":"Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 2015;15:106.","journal-title":"Cancer Cell Int"},{"key":"4330_CR43","doi-asserted-by":"publisher","first-page":"58489","DOI":"10.1021\/acsami.4c15320","volume":"16","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Ouyang AL, Fan L, Qin X, Li Y, Wang ZX, Yuan PY, Huang XJ, Hao J, Zhu HY, et al. Precision Delivery of Binary Cooperative Nanodrugs Self-Assembled by Berberine Glycyrrhetinic Acid Salts for Hepatocellular Carcinoma Treatment. ACS Appl Mater Interfaces. 2024;16:58489\u2013505.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4330_CR44","doi-asserted-by":"publisher","first-page":"163582","DOI":"10.1016\/j.cej.2025.163582","volume":"515","author":"J Tang","year":"2025","unstructured":"Tang J, Chen Y, Lai H, Zeng Q, Li Y, Feng J, Lin N, Jin R, Liu J, Luo T, Liang Z. Innovative immunosonogen nanoplatform combining sonodynamic oxygenation and immunomodulation for superior cancer therapy. Chem Eng J. 2025;515:163582.","journal-title":"Chem Eng J"},{"key":"4330_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1158\/1940-6207.CAPR-21-0227","volume":"15","author":"DL Cecil","year":"2022","unstructured":"Cecil DL, Gad EA, Corulli LR, Drovetto N, Lubet RA, Disis ML. COX-2 inhibitors decrease expression of PD-L1 in colon tumors and increase the influx of type I tumor-infiltrating lymphocytes. Cancer Prev Res. 2022;15:225\u201331.","journal-title":"Cancer Prev Res"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04330-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04330-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04330-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:02:35Z","timestamp":1783659755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04330-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4330"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04330-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal care and experimental protocols were approved by the Institutional Animal Ethics Committee of Guangxi Medical University (Approval No. 202409025). Mice were humanely euthanized once the tumor reached 10\u201315\u00a0mm in diameter. Mice were terminated via cervical dislocation (an authorized schedule 1 procedure). No anesthetic or drugs were involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"642"}}